Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer.

ABSTRACT: Recent work demonstrates that castration-resistant prostate cancer (CRPC) tumors harbor countless genomic aberrations that control many hallmarks of cancer. While some specific mutations in CRPC may be actionable, many others are not. We hypothesized that genomic aberrations in cancer may operate in concert to promote drug resistance and tumor progression, and that organization of these genomic aberrations into therapeutically targetable pathways may improve our ability to treat CRPC. To identify the molecular underpinnings of enzalutamide-resistant CRPC, we performed transcriptional and copy number profiling studies using paired enzalutamide-sensitive and resistant LNCaP prostate cancer cell lines. Gene networks associated with enzalutamide resistance were revealed by performing an integr

SUBMITTER: King CJ 

PROVIDER: S-EPMC5762307 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature